

Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel

Authors and Affiliations:

Michael T. Parsons¹, Miguel de la Hoya², Marcy E. Richardson³, Emma Tudini¹, Michael Anderson⁴, Windy Berkofsky-Fessler⁵, Sandrine M. Caputo⁶, Raymond C. Chan⁷, Melissa C. Cline⁸, Bing-Jian Feng⁹, Cristina Fortuno¹, Encarna Gomez-Garcia¹⁰, Johanna Hadler¹, Susan Hiraki⁵, Megan Holdren¹¹, Claude Houdayer¹², Kathleen Hruska⁵, Paul James¹³, Rachid Karam³, Huei San Leong¹⁴, Alexandra Martins¹⁵, Arjen R. Mensenkamp¹⁶, Alvaro N. Monteiro¹⁷, Vaishnavi Nathan¹, Robert O'Connor⁷, Inge Sokilde Pedersen¹⁸⁻²⁰, Tina Pesaran³, Paolo Radice²¹, Gunnar Schmidt²², Melissa Southey²³⁻²⁵, Sean Tavigian²⁶, Bryony A. Thompson²⁷, Amanda E. Toland²⁸, Clare Turnbull²⁹, Maartje J. Vogel³⁰, Jamie Weyandt³, George A.R. Wiggins³¹, Lauren Zec³², Fergus J. Couch¹¹, Logan C. Walker³¹, Maaïke P. G. Vreeswijk³³, David E. Goldgar⁹, Amanda B. Spurdle^{1,34}

¹ Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.

² Molecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.

³ Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA.

⁴ Invitae Corporation, San Francisco, CA, USA.

⁵ GeneDx, Gaithersburg, Maryland, USA.

⁶ Department of Genetics, Institut Curie, 75005 Paris, France and Paris Sciences Lettres Research University, Paris, 75005, France.

⁷ Color Health, Burlingame, CA, USA.

⁸ UC Santa Cruz Genomics Institute, Mail Stop: Genomics, University of California, 1156 High Street, Santa Cruz, CA, 95064, USA.

⁹ Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.

¹⁰ Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands.

¹¹ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

¹² Univ Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Genetics, FHU G4 génomique F-76000 Rouen, France.

¹³ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.

¹⁴ Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia.

¹⁵ Univ Rouen Normandie, Inserm U1245, F-76000 Rouen, France.

¹⁶ Department of Human Genetics, Radboud university medical center, Nijmegen, the Netherlands.

¹⁷ Department of Cancer Epidemiology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.

¹⁸ Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.

¹⁹ Dept. of Clinical Medicine, Aalborg University, Denmark.

²⁰ Clinical Cancer Research Center, Aalborg University Hospital, Denmark.

²¹ Predictive Medicine: Molecular Bases of Genetic Risk, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milano, Italy.

²² Institute of Human Genetics, Hannover Medical School, 30625 Hannover, Germany.

²³ Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VC, Australia.

²⁴ Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, 3168, Australia.

²⁵ Department of Clinical Pathology, The Melbourne Medical School, The University of Melbourne, Victoria, 3010, Australia.

²⁶ Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA.

²⁷ Department of Pathology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.

²⁸ Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH 43210, USA.

²⁹ Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.

³⁰ Department of Human Genetics, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

³¹ Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.

³² Natera, Inc, San Carlos, CA, USA.

³³ Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands.

³⁴ Faculty of Medicine, University of Queensland, Australia.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

52 **Abstract**

53
54 The ENIGMA research consortium (<https://enigmaconsortium.org/>) develops and applies methods to determine clinical significance
55 of variants in Hereditary Breast and Ovarian Cancer genes. An ENIGMA *BRCA1/2* classification sub-group, originally formed in 2016
56 as a ClinGen external expert panel, evolved into a ClinGen internal Variant Curation Expert Panel (VCEP) to align with Federal Drug
57 Administration recognized processes for ClinVar contributions.

58 The VCEP reviewed American College of Medical Genetics/Association of Molecular Pathology (ACMG/AMP) classification criteria
59 for relevance to interpreting *BRCA1* and *BRCA2* variants. Statistical methods were used to calibrate evidence strength for different
60 data types. Pilot specifications were tested on 40 variants, and documentation revised for clarity and ease-of-use.

61 The original criterion descriptions for 13 evidence codes were considered non-applicable or overlapping with other criteria. Scenario
62 of use was extended or re-purposed for eight codes. Extensive analysis and/or data review informed specification descriptions and
63 weights for all codes. Specifications were applied to pilot variants with pre-existing ClinVar classification as follows: 13 Uncertain
64 Significance or Conflicting, 14 Pathogenic and/or Likely Pathogenic, and 13 Benign and/or Likely Benign. Review resolved
65 classification for 11/13 Uncertain Significance or Conflicting variants, and retained or improved confidence in classification for the
66 remaining variants.

67 Alignment of pre-existing ENIGMA research classification processes with ACMG/AMP classification guidelines highlighted several
68 gaps in both the research processes and the baseline ACMG/AMP criteria. Calibration of evidence types was key to justify utility and
69 strength of different evidence types for gene-specific application. The gene-specific criteria demonstrated value for improving
70 ACMG/AMP-aligned classification of *BRCA1* and *BRCA2* variants.

71
72 **Keywords**

73 BRCA1; BRCA2; ClinGen; VCEP; ACMG/AMP variant curation guidelines; ClinVar
74
75

76 Introduction

77 The role of *BRCA1* (MIM 113705) and *BRCA2* (MIM 600185) in Hereditary Breast and Ovarian Cancer (HBOC) has long been
78 recognized, with genetic testing initiated soon after discovery of these genes in the 1990s.^{1,2} The ENIGMA international research
79 consortium (<https://enigmaconsortium.org/>)³ focuses on development and application of methods to determine the clinical
80 significance of sequence variants in HBOC genes. The consortium has members from six continents that provide a broad range of
81 expertise, under the umbrellas of analytical, splicing, functional, pathology and clinical working groups, for translational research
82 projects. At the request of ClinGen, in 2016 ENIGMA formed an external expert panel for curation of *BRCA1* and *BRCA2* variants.
83 The classification criteria documented for this purpose (no longer used, Supplemental Information, Section 1) captured qualitative
84 criteria generally adopted clinically (e.g., most premature termination codon variants were assumed to be pathogenic), and
85 quantitative multifactorial likelihood analysis methods developed in the research setting.⁴⁻⁸ The key component of the multifactorial
86 likelihood approach is the statistical calibration of independent data types using variants of known pathogenicity status, to inform the
87 weight of evidence towards or against pathogenicity. The external expert panel guidelines were then used to assign 7,456 expert
88 curations for *BRCA1* and *BRCA2* variants in ClinVar.

89 In parallel to these efforts, there was increasing international uptake of variant classification guidelines published by the American
90 College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP)⁹ for diagnostic interpretation of
91 germline sequence variants, with applicability to any Mendelian disease gene. In 2020, the ENIGMA external expert panel sought to
92 become an internal ClinGen Variant Curation Expert Panel (VCEP),^{10, 11} to align with Federal Drug Agency (FDA) recognized
93 processes for expert panel contributions to ClinVar. Here, we provide an overview of the evidence-based approach taken to consider
94 relevance of each ACMG/AMP evidence code for curation of variants in *BRCA1* and *BRCA2*, and report pilot study results
95 demonstrating the value of detailed (gene-specific) specifications to assist variant curation and resolve discordances and uncertainty
96 in variant classification.

97 Methods

98 The establishment and activities of the ClinGen *BRCA1* and *BRCA2* VCEP followed the ClinGen FDA-recognised approval process
99 (<https://clinicalgenome.org/docs/guidelines-for-applying-for-variant-or-gene-curation-expert-panel-status/>), with reference to
100 Protocol Version 8 at the time of VCEP initiation.

101 The original ENIGMA *BRCA1* and *BRCA2* expert panel membership, which was largely comprised of representatives from major
102 national clinical and research initiatives in Australia, Europe and USA, was expanded to include representatives from several major

103 diagnostic testing laboratories from the United States with extensive experience in the application of ACMG/AMP guidelines. The
104 resulting ClinGen ENIGMA *BRCA1* and *BRCA2* VCEP consists of research and clinical experts from around the world, including
105 Australasia, Europe and the United States. VCEP members met approximately monthly to review the baseline ACMG/AMP sequence
106 variant classification guidelines⁹ to determine whether each classification criterion should be adopted, modified, or omitted for *BRCA1*
107 and *BRCA2* variant interpretation.

108 Both *BRCA1* and *BRCA2* were designated as genes for which loss of function is a known mechanism of disease. Reference
109 sequences used for annotation are as follows:

110 *BRCA1*. Coding DNA reference sequence from genomic RefSeq NG_005905.2 (same as LRG 292, Ensembl ENSG0000012048)
111 covering *BRCA1* transcript NM_007294.4 (Ensembl transcript ENST00000357654.9). Exons are sequentially numbered to match
112 the exon descriptions of the MANE Select transcript (NM_007294.4). Exon numbering of *BRCA1* has historically been according to
113 GenBank U14680.1, with exon 4 missing due to a correction made after the initial description of the gene, termed here as legacy
114 exon numbering.

115 *BRCA2*. Coding DNA reference sequence from genomic RefSeq NG_012772.3 (same as LRG 293, Ensembl ENSG00000139618),
116 covering *BRCA2* transcript NM_000059.4 (MANE Select transcript; Ensembl transcript ENST00000380152.8).

117
118 The classification tiers in pre-existing ENIGMA external panel classification criteria for *BRCA1* and *BRCA2* (Supplemental
119 Information, Section 1) grouped multiple sources of information (e.g. frequency data, variant type, tumor pathology, co-occurrence
120 with a pathogenic variant, etc). A critical aspect of VCEP activities was to convert these grouped criteria to align with ACMG/AMP
121 codes representing different classification criteria, falling under the broad evidence types described for the ACMG/AMP framework
122 (i.e. population, computation/predictive, functional, segregation, de novo, allelic, other).⁹ Statistical methods were used to calibrate
123 strength of evidence (i.e. supporting, moderate, strong, very strong and stand-alone) for different data types following approaches
124 as outlined previously; and likelihood ratio (LR) estimates towards or against pathogenicity were derived for a given evidence type ¹²
125 and used to assign weights for or against pathogenicity following recommendations arising from Bayesian modelling of the
126 ACMG/AMP guidelines.¹³ Alongside, key members of the ClinGen Sequence Variant Interpretation Working Group (SVI WG)
127 (<https://clinicalgenome.org/working-groups/sequence-variant-interpretation/>) were consulted about how to capture valuable
128 information sources and analytical approaches that were used previously for external expert panel classification, but that did not
129 strictly conform to ACMG/AMP evidence types and designated codes/strengths. Extensive documentation supporting the rationale
130 for application and weighting of each code was compiled for ClinGen SVI WG review, following the standard VCEP approval protocol.

131 Specifications for codes relating to the use of computational and experimental evidence relevant to variant impact on RNA splicing
132 were informed by parallel development of recommendations from the ClinGen SVI Splicing Subgroup.¹⁴ After addressing feedback
133 from the SVI WG, the draft documentation was provided to nine VCEP members who had self-nominated to act as biocurators. As
134 biocurators they review and evaluate evidence relevant for variant classification, assign relevant ACMG/AMP codes and weights for
135 the available evidence, and ascribe a final pathogenicity classification based on the information reviewed. The draft specifications
136 were tested on 40 pilot variants, selected to capture variants spanning different assumed molecular impact, and different pre-existing
137 classifications in ClinVar (Supplemental Information, Section 2, Table S1). VCEP members were requested to provide any internal
138 data of relevance for classification of these 40 variants. Initial ClinVar summary classification descriptions were as follows: Pathogenic
139 (P), n=11; Likely Pathogenic/Pathogenic (LP/P), n=3; Uncertain Significance (VUS), n=4; Benign/Likely Benign (B/LB), n=1; Benign
140 (B), n=12; Conflicting, n=9. Conflicting Classifications represented various combinations of individual submitter classifications (details
141 provided in Table S1).

142 To facilitate the curation process, each biocurator was provided a file with the following variant-specific information: population
143 frequency as reported in gnomAD (v2.1 exomes only and v3.1); existing multifactorial LR data (spanning segregation, family history,
144 tumour pathology, case-control and co-occurrence LRs); protein functional assay data; mRNA splicing assay data; bioinformatic
145 impact predictions (missense, in-frame, splicing); clinical features of Fanconi Anemia (FA) cases as drawn from the literature and
146 additional internal laboratory data relevant for classification as provided by VCEP members. The latter included splicing assay results,
147 co-segregation data, presence or absence of FA phenotype for individuals with co-occurring variants. Protein functional assay data
148 was provided with functional category (impact, no impact or partial/indeterminate) assigned for all functional assays considered
149 relevant, with a summary description of the combined results. RNA assay data required evaluation by individual biocurators to assign
150 code weights. Each variant was curated by the lead biocurator (MTP) and two additional biocurators. The lead biocurator reviewed
151 curations for consistency in code application (including code strength), and final variant classification. Collated findings were
152 discussed with all VCEP members to identify factors contributing to between-biocurator differences in use of the specifications.

153 After this initial phase of variant review, biocurator feedback was used to inform revision of the documentation for clarity and ease of
154 use. This included development of simplified look-up tables. At this time codes relating to bioinformatic predictions were updated to
155 allow three categories: evidence towards pathogenicity, against pathogenicity and no bioinformatic code applicable. These updates
156 were based on results from published splicing prediction analyses¹⁴, and VCEP-specific re-analysis conducted to refine calibrations
157 for missense prediction.

158 The revised documentation was then used for a second phase of the pilot curation. Variants classified with inter-biocurator differences
159 including at least one VUS and one non-VUS classification, labelled as “VUS/other”, were reviewed by two additional VCEP
160 biocurators. Variants with classification confidence differences (P versus LP, or B versus LB) were reviewed by one independent
161 biocurator with extensive experience from the ClinGen *TP53* VCEP. Finally, code assignment was checked for all variants with
162 concordant classification from the first pilot phase, by two VCEP biocurators. Further minor revisions were introduced following
163 biocurator feedback on the revised documentation, and after final review from the ClinGen SVI WG.

164 Results and Discussion

165 An overview of the migration of the ENIGMA external expert panel to current operation as a ClinGen-approved VCEP, following FDA-
166 recognized processes, is shown in Figure 1. Development and documentation of the specifications was an iterative process that
167 involved: (i) discussions and/or review at multiple levels (within the ClinGen SVI WG, and the VCEP members); (ii) coordination with
168 and consideration of other ClinGen activities - including other ClinGen Hereditary Cancer Domain VCEPs, the ClinGen SVI Splicing
169 Subgroup¹⁴, and a subgroup of the ClinGen SVI WG focussed on calibration of computational tools for missense prediction¹⁵. The
170 extended timeline reflects the evidence-based approach taken to justify - to both VCEP and ClinGen SVI WG members - the
171 appropriateness and/or strength of different information sources for application to *BRCA1* and *BRCA2* variants.

173 [Overview of *BRCA1* and *BRCA2* Specifications](#)

174
175 A broad outline of the evidence informing specifications for each baseline ACMG/AMP code is shown in Figure 2. A summary of the
176 specifications designated for each ACMG/AMP code is described in Supplemental Information, Section 2, Table S2, together with a
177 brief description of mode of application or reasons for excluding a given code. The complete ClinGen SVI WG approved specifications
178 for *BRCA1* and *BRCA2* VCEP are available via the ClinGen C-spec registry
179 (<https://cspec.genome.network/cspec/ui/svi/affiliation/50087>), together with supporting documentation, and an extensive 50 page
180 document with appendices describing analyses and justifications for code applicability and weighting. These specifications are
181 expected to be updated over time to follow on scientific knowledge progress, and version changes will be documented via this same
182 portal. Summary findings reported in this study refer to Version 1.0 specifications and supporting documentation, also included here
183 as Supplemental Information, Section 3.

184 After initial review of ACMG/AMP criteria for relevance to interpretation of *BRCA1* and *BRCA2* variants, the original criterion
185 descriptions for 13 codes were considered non-applicable to these genes or overlapping (non-independent) with other criteria, largely
186 based on expert opinion (Figure 2, Table S2). Specific examples were: PS2/PM6 (de novo), given that *BRCA1/2*-related cancers are
187 common, and there was no information available to calibrate use of this information type; PM1 (location in a hot spot or critical
188 domain), since this was considered to be captured as a component of bioinformatic analysis, since missense prediction tools
189 inherently capture this information. In addition, directed calibration analysis was undertaken to justify that generalised use of proband
190 counting as PS4_Moderate is inappropriate for these genes due to overlap with frequency codes, and variability in evidence strengths
191 observed between cohorts.¹⁶

192 Specifications were denoted for 15 codes. Extensive data review and/or analysis from previous ENIGMA-wide and/or VCEP activities
193 was used to inform processes and relevant weights applicable for most of these 15 codes, as described in comprehensive
194 supplementary documentation provided with the VCEP specifications, captured as V 1.0 in Supplemental Information, Section 3. (All
195 versions of specifications are made available via the ClinGen online registry for VCEP specifications.
196 <https://cspec.genome.network/cspec/ui/svi/>). Several specifications were implemented specifically to follow recommendations from
197 parallel work of the ClinGen SVI Splicing Subgroup¹⁴: codes PVS1, PS1, and BP7 were extended to capture RNA splicing
198 experimental data or *in silico* predictions; PS3 and BS3 were restricted to capture results from assays that measure protein functional
199 effect (either only protein impact, or protein impact that also measures underlying mRNA impact/s); and splicing impact thresholds
200 defined for SpliceAI were set for bioinformatic prediction of variant impact on splicing, captured under various codes. Probability
201 analysis combined with LR estimation¹⁷ was used to select and weight bioinformatic tool score categories for missense variant
202 prediction under PP3 and BP4. BayesDel was selected as tool of choice based on results from heterogeneity analysis, performance
203 compared to similar tools, and this tool was able to provide scores for in-frame indels. Extended calibration analysis was undertaken
204 during the pilot phase (Supplemental Information, Section 2) to include an uninformative bioinformatic score range category, and
205 specifically to compare BayesDel score categories to those recommended for general use by Pejaver et al.¹⁵, published during the
206 VCEP specification process. The optimal binary cutpoint for BayesDel score prediction of impact for a missense variant within a
207 clinically important functional domain was 0.27 for *BRCA1* and 0.20 for *BRCA2* (Figure S1). The binary cutpoint values were used to
208 designate the central point for an uncertain zone comprised of <20% of each reference set, and for which the outer score categories
209 provided at least moderate evidence towards or against pathogenicity based on estimated LR. The VCEP opted, conservatively, to
210 apply this evidence type at supporting weight only (Table 1). Optimal BayesDel score ranges across three categories for both *BRCA1*
211 and *BRCA2* missense prediction (Table 1) did not align with those recommended for generic use by Pejaver et al.¹⁵ (Table S3).

Specifically, use of the Pejaver et al. scale performed very poorly for benign reference set variants, in that a BP4 code (at minimum supporting strength for BayesDel ≤ -0.18) would be assigned to $< 10\%$ of *BRCA1* and *BRCA2* benign reference set variants, with the large majority having no code applicable. Further, a considerable proportion (29% for *BRCA1*, 36% for *BRCA2*) would be incorrectly assigned PP3 at minimum supporting evidence strength, for BayesDel ≥ 0.13 .

Specification of the frequency codes PM2/BS1/BA1 was informed by a combination of LR-based methods¹⁷, and minimal credible allele frequency estimation¹⁸ as recommended by ClinGen. LR estimation approaches previously used for weighting combined results from functional assays¹² were repeated using an expanded dataset, and confirmed applicability of PS3 and BS3 at Strong level. Extensive review of the literature and consideration of FA-designated features in GeneReviews (<https://www.ncbi.nlm.nih.gov/books/NBK1401/>) informed the use of presence or (apparent) absence of FA phenotype for application of codes PM3 and BS2, respectively. Recommendations for use and weighting of segregation data for codes PP1 and BS4 built on methods previously established and enhanced for *BRCA1* and *BRCA2* variant interpretation by the ENIGMA consortium,^{8, 19} which consider gene-specific age-specific cumulative risk (penetrance) and background population incidence in assessing variant causality.

The application (i.e. "criterion" description) was completely re-purposed for four codes in consultation with the ClinGen SVI WG, after consideration of empirical data on *BRCA1/2*-related clinical features. PM5 was designated to assign exon-specific weights for a premature termination codon (PTC) variant found in an exon in which functional data and/or case-control burden analysis and/or family history burden analysis proves that PTCs in the exon are indeed pathogenic (as justified by VCEP analysis, Figure 3). BP1 was used to capture strong evidence against pathogenicity for a variant outside of a known clinically important functional domain predicted to encode a silent or missense/in-frame substitution only (without known or predicted impact on splicing), with strength assigned from probability based studies¹⁷, and VCEP consideration of large-scale case-control findings for missense variants.^{20, 21} PP4 and BP5 were repurposed to capture combined LR estimates towards pathogenicity (PP4) or against pathogenicity (BP5), as derived from calibrated multifactorial likelihood ratio analysis (but excluding any direct statistical measurement of bioinformatic prediction scores, to avoid overlap with other computational codes).

Key considerations during development of the *BRCA1* and *BRCA2* specifications

Major points for discussion with key ClinGen SVI WG members before and during documentation of the draft specifications included codes capturing bioinformatic or experimental impact on mRNA splicing; these were later resolved in part by review conducted under

239 the umbrella of the ClinGen SVI Splicing Subgroup. Extensive discussion of additional codes, which at the time were new requests
240 for code adaptations by a VCEP, included:

- 241 ● downgrading PM2 (absence in population databases) to PM2_supporting, informed by parallel research¹⁷
 - 242 ● adapting the PVS1 decision tree recommendations for weighting predicted loss of function variants²² to consider
 - 243 ◆ the importance of naturally occurring rescue isoforms²³
 - 244 ◆ functional domains designated as clinically important based on location of known pathogenic missense variants (as per
245 ClinGen-approved external expert panel criteria for *BRCA1* and *BRCA2* (Supplemental Information, Section 1)
 - 246 ◆ duplications that preserve reading frame
 - 247 ◆ splice donor/acceptor $\pm 1,2$ dinucleotide variants for exons outside of the coding exons (5' or 3' UTRs)
 - 248 ◆ splice donor $\pm 1,2$ dinucleotide variants that create *de novo* predicted functional "GC" 5' splice sites
 - 249 ● repurposing PM5 to capture exon-specific evidence as additional information for classification of predicted loss of function
250 stop and frameshift variants, motivated by existing clinical evidence that PTC variants are highly likely to be pathogenic
 - 251 ◆ variants in the AG-GT splice site positions do not qualify for PM5 (PTC) code, since the mechanism of impact on mRNA
252 transcripts may introduce variability in proportion of loss of function transcripts produced
 - 253 ● considering that protein domain combined with missense bioinformatic predictions, and clinical data from published case-
254 control data, achieves greater predictive value than bioinformatic missense prediction alone, and acceptance that an
255 upweighted repurposed BP1_Strong code for missense and synonymous variants outside of a known (likely) clinically
256 important protein domain is sufficient to achieve likely benign classification for *BRCA1* and *BRCA2* variants
 - 257 ● repurposing PP4 and BP5 to capture likelihood data for multiple evidence types calibrated to predict pathogenicity
 - 258 ◆ expanding potential to provide evidence against pathogenicity for data types previously only considered as positive
259 predictors of pathogenicity e.g. case-control OR can be applied as PS4 only, but case-control LR estimates could be
260 applied as PP4 or BP5
 - 261 ◆ increasing the breadth of information types that might be used for variant interpretation, even if not explicitly or directly
262 captured by existing ACMG/AMP criteria e.g. breast tumor pathology features predictive of *BRCA1* or *BRCA2* variant
263 pathogenicity are not specific to individuals with a pathogenic variant in these genes
 - 264 ◆ allowing combined likelihoods to be captured under a single code
 - 265 ◆ facilitating alignment with pre-existing variant classifications based on multifactorial likelihood analysis
- 266

267 There was also resolution to align code combinations to achieve variant classes following recommendations arising from Bayesian
268 modelling of the ACMG/AMP classification system¹³, and agreement to use the points approach²⁴ to justify expansion of benign code
269 combinations to include benign codes at moderate strength level, and use of the points approach to resolve classifications for variants
270 with discordant benign and pathogenic code application.

271 272 Pilot application of specifications for *BRCA1* and *BRCA2* classification

273
274 An overview of the classifications during and after the pilot curation process is shown in Figure 4. Classifications assigned to the 40
275 pilot variants at the first and second curation phases, and the final classification assigned (with codes applied) are detailed in Table
276 S1. Pre-existing ClinVar classification for the pilot variants, based on all submitter variant assertions at the time of extraction, was as
277 follows: 13 VUS/conflicting, 11 P, 3 LP/P, 1 LB/B, and 12 B. After initial review, 32/40 variants achieved classification within a
278 confidence band (LP/P or LB/B). Review of the classifications identified several reasons for the differences: new pieces of
279 unpublished internal information used by one biocurator only; unfamiliarity with data presentation; need for clarification of code use.
280 Between-curator differences often involved: recoding of published multifactorial likelihood data to ACMG/AMP codes PP4 and BP5
281 (23/40); use of frequency information (16/40); use of bioinformatic data (17/40); weighting of splicing data and use of functional data
282 (15/40). Biocurator feedback indicated the need for more specific advice for some codes, simplified tables and figures in a single
283 “specifications” document, and more detailed recommendations for interpretation of mRNA splicing data. Documentation was revised
284 accordingly, including development and inclusion of an RNA rubric for weighting of mRNA assay data. At this point, additional
285 calibration analysis was undertaken to reassess BayesDel score cut points (as per Table 1), and results incorporated into the revised
286 specifications.

287 After re-review in the second curation phase, six of eight variants assigned to “VUS/other” group in the first phase were resolved to
288 a single classification. For variants with classifications that differed in confidence, 5/6 LP/P and all 3 LB/B resolved to a more certain
289 classification (i.e. P or B). Compared to the original ClinVar class, classification was resolved for 11/13 VUS/conflicting variants (5 P,
290 1 LP, 2 VUS, 3 LB, 2 B). All variants with pre-existing ClinVar class P (11 variants) or B (12 variants) retained class. Of the remainder,
291 3 LP/P variants were upgraded to P, and a single LB/B variant was classified as B. As expected, variants annotated with missense
292 or intronic molecular consequences showed greater classification uncertainty and variability (considering conflicts and confidence

293 differences) compared to premature termination codon and synonymous variants, in both initial ClinVar classification and at the first
294 VCEP curation step (see Table S1 for details).

295 Further minor revisions of the specifications and appendices were introduced following biocurator feedback, and after final review
296 from the ClinGen SVI WG.

298 [Conclusions and future directions](#)

299
300 Alignment of pre-existing *BRCA1* and *BRCA2* ENIGMA classification processes with ACMG/AMP classification criteria highlighted
301 several gaps in both the pre-existing processes and in the baseline ACMG/AMP criteria. Statistical calibration of different evidence
302 types was key to justify acceptance – or rejection - of the utility of different ACMG/AMP evidence codes for classification by VCEP
303 members, and also the ClinGen SVI WG overseeing VCEP approval. Functional evidence was lacking from the pre-existing ENIGMA
304 external panel criteria for *BRCA1* and *BRCA2* (Supplemental Information, Section 1), and the requirement to align with ACMG/AMP
305 processes provided motivation and mechanism for the VCEP to define suitable data sources and reach consensus on specifications
306 for this evidence type. Regarding the codes/criteria deemed not applicable, VCEP member individual opinion concerning the utility
307 of proband-counting criterion was sufficiently contentious that a separate sub study was conducted. This study demonstrated that
308 proband counting with comparison to population datasets is not sufficiently robust for generic application for *BRCA1* and *BRCA2*,
309 given that these genes lead to relatively common diseases.¹⁶ Major items for discussions with key members of the ClinGen SVI WG
310 revolved around the need for ACMG/AMP criteria to be adapted or repurposed to capture more evidence types (and strengths), in
311 particular to provide evidence against pathogenicity. Agreement by the ClinGen SVI WG to adapt an existing code PM5 provided a
312 mechanism for additional exon-specific weighting so that pre-existing diagnostic laboratory classification practices for *BRCA1* and
313 *BRCA2* PTC variants would not be reversed on introduction of ACMG/AMP classification system (unless indicated by evidence in
314 this process).

315 The alignment of pre-existing ENIGMA classification methods with ACMG/AMP processes has led to benefits beyond interpretation
316 of variants in *BRCA1* and *BRCA2*. The research-driven consideration of evidence types and calibration by the ENIGMA *BRCA1* and
317 *BRCA2* VCEP informed the activities of the SVI Splicing Subgroup, and has already led to uptake of some of the “*BRCA1/BRCA2*”
318 specifications for ACMG/AMP criteria by other ClinGen VCEPs. These have included: introduction of bioinformatic tiers for splicing
319 prediction; consideration of RNA data under the PVS1 decision process; consideration of read depth for annotation of frequency

320 codes;^{25, 26} alignment of weights (for recessive disease) with *PALB2*, another gene associated with Fanconi Anemia; uptake of the
321 PM5 code use for PTC variants in multiple other genes (including *ATM*, *CDH1*, *PALB2*, and *RUNX1*). It is also notable that some of
322 these adaptations have been taken forward for the draft iteration of the next version of the ClinGen-promoted classification guidelines
323 for application to any Mendelian gene.

324 The ClinGen ENIGMA *BRCA1* and *BRCA2* VCEP has now initiated ACMG/AMP-aligned review of *BRCA1* and *BRCA2* variants in
325 ClinVar. As a priority the VCEP is reviewing variants with conflicting assertions and will shortly re-assess pre-existing external expert
326 panel curations to highlight any variants expected to alter in classification after application of the VCEP specifications. VCEP review
327 of all *BRCA1* and *BRCA2* variants in ClinVar will be an extensive and time-consuming effort, both due to the enormity of the task
328 (11,932 *BRCA1* and 17,109 *BRCA2* variants as at 1st November 2023) and constraints associated with the rigorous FDA-aligned
329 ClinGen protocol. For example, after biocurator assessment of information and classification by code assignment and manual entry
330 into the ClinGen Variant Curation Interface,²⁷ three core approvers are required to review and agree with the classification. The VCEP
331 aims to introduce additional efficiencies to ease the load of biocurators in variant review, such as algorithmic code assignment based
332 on frequency and computational information in the BRCA Exchange portal (<https://brcaexchange.org/>)²⁸, as a means to prioritize
333 variants for additional data collection and review. This portal will also provide a mechanism for public dissemination of VCEP-aligned
334 ACMG/AMP codes for *BRCA1* and *BRCA2* variants ahead of formal VCEP review.

335 In summary, this work has provided extensive evidence-based specifications to enable standardized and improved classification of
336 variants in *BRCA1* and *BRCA2*. Further, it has more widely informed improvements in both gene-specific and generic application of
337 the ACMG/AMP classification guidelines.

339 **Declaration of Interests**

340 M.A. was a paid employee of Invitae. R.C.C. and R.O. are paid employees of Color Health. M.E.R., T.P. and R.K. are paid
341 employees of Ambry Genetics. A.R.M. and M.J.V. received funds from AstraZeneca for contribution to sponsored quality
342 assessments and variant interpretation of *BRCA1* and *BRCA2* VUS (funds paid to the institution).

343 **Acknowledgments**

344 Refer to Supplemental Information Section 2.

345 **Author contributions**

346 All authors contributed to conceptualization and writing (review and editing). Funding acquisition by F.J.C. and A.B.S. Data curation
347 by M.T.P., E.T., L.C.W., M.d.I.H., and A.B.S. Formal analysis conducted by D.E.G., M.T.P, B-J.F., G.A.R.W, L.C.W., M.d.I.H., V.N.,
348 M.E.R, and A.B.S. Investigation by M.T.P., W.B-F., R.C.C., M.d.I.H., S.H., M.H., H.S.L., A.R.M., R.O., M.E.R., G.S., I.S.P., B.A.T.,
349 M.P.G.V., L.Z., C.F. and J.H. All authors read and approved the final manuscript.

350 **Web resources**

351 URLs are provided in the text where appropriate.

352 **Data and code availability**

353 The published article includes all datasets generated or analyzed during this study.
354

Table 1: LR towards pathogenicity for BayesDel categories selected for *BRCA1* and *BRCA2* VCEP specifications

Gene	BayesDel Score Category	Benign ¹	%	Pathogenic ¹	%	LR towards Pathogenicity	95% Confidence Interval	ACMG code weight applicable based on LR	ACMG bioinformatic code and weight recommended for <i>BRCA1/BRCA2</i> specifications ²
<i>BRCA1</i>	≤ 0.15	946	74%	34	7%	0.10	0.07-0.14	Moderate Benign	Supporting Benign (BP4)
	> 0.15 and < 0.28	183	14%	45	10%	0.69	0.51-0.94	No Evidence	No Evidence (not met)
	≥ 0.28	149	12%	377	83%	7.09	6.06-8.30	Moderate Pathogenic	Supporting Pathogenic (PP3)
<i>BRCA2</i>	≤ 0.18	216	74%	21	16%	0.21	0.14-0.33	Moderate Benign	Supporting Benign (BP4)
	> 0.18 and < 0.30	46	16%	25	19%	1.18	0.73-1.90	No Evidence	No Evidence (not met)
	≥ 0.30	29	10%	88	66%	6.59	4.40-9.90	Moderate Pathogenic	Supporting Pathogenic (PP3)

¹ Benign reference set variants were assumed benign based on no functional impact, and Pathogenic reference set variants were assumed pathogenic based on full functional impact. Based on extensive previous calibration analysis, missense prediction is considered relevant only for missense variants located within known (likely) clinically-important functional domains, and reference set variants were drawn from these regions only. See *BRCA1/2* VCEP specifications V1.0 for data sources and coding (Supplemental information, Section 3).

² Recommendation based on consensus opinion of VCEP members was to conservatively apply bioinformatic evidence at maximum Supporting weight




Figure 1: Timeline for migration from “external” expert panel to operation as a ClinGen Variant Curation Expert Panel following the ClinGen FDA-recognized protocol.

Discussions with key members of the SVI WG during 2019 relating to the strategy for alignment included the need to capture information sources used previously for *BRCA1* and *BRCA2* variant interpretation that are not explicitly designated under the baseline ACMG/AMP guidelines, especially information used in the context of multifactorial likelihood modelling. Revision of specifications at Step 3 included updates in response to ClinGen SVI Splicing subgroup recommendations¹⁴, and re-calibration of bioinformatic prediction of missense impact in response to ClinGen SVI Computational subgroup recommendations.¹⁵ Details of ENIGMA *BRCA1* and *BRCA2* Variant Curation Expert Panel membership and biocurator workforce are available at <https://clinicalgenome.org/affiliation/50087/>. Pre-existing ENIGMA expert panel classification guidelines for *BRCA1* and *BRCA2* are shown in Supplemental Information, Section 1, as point of reference (though no longer currently used). The final specifications approved for internal ClinGen *BRCA1/2* VCEP use are available via <https://cspec.genome.network/cspec/ui/svi/affiliation/50087>.



Considerations for specification	Code	Brief description of criterion	Rationale & Criterion range of purpose	Evidence strength change	
Codes/criteria deemed not applicable - largely informed by expert opinion 	PS2, PM6	De novo	No data	N/A	
	PS4_Moderate	Proband-counting	Non-independent of population frequency, between-cohort variability	N/A	
	PM1; PM4, BP3	Hotspot; Protein length changes	Non-independent of other bioinformatic predictions	N/A	
	PP2, BP2	Gene/clinical/syndrome-related features	Irrelevant, based on consensus opinion	N/A	
	PP5, BP6	Presence in databases	Criterion abandoned, as per ClinGen recommendation	N/A	
Criterion descriptions and strengths specified after data review and analysis (previous studies, or this study) 	PVS1	Null variant	Extended – proven splicing impact captured as PVS1 (RNA)	Yes, Variable	
	PS3, BS3	Functional data	Restricted – excludes splicing-only assay data	No	
	PS1	Same missense as pathogenic variant	Extended – same splicing prediction as known pathogenic variant	Yes, Variable	
	PM2, BA1, BS1	Population frequency	Calibration informed designation of frequency bins and assigned evidence strengths	Yes	
	PM3, BS2	Recessive presentation	Data review informed clinical criteria descriptions	Yes, Variable	
	PP3, BP4	Bioinformatic prediction	Calibration informed designation of score categories, including a central uninformative range	No	
	BP7			Extended - intronic variants	No
				Extended - splicing data captured as BP7 (RNA)	Yes, Strong
	PS4	Case-Control odds ratio	Note: Preferentially apply as case-control LR (PP4, BP5)	No	
PP1, BS4	Co-segregation	Extended – captures age-specific penetrance models	Variable		
Codes repurposed to align with existing evidence-based protocols.	PM5	Missense change at residue with another pathogenic missense >> Protein termination codon (PTC) variant in an exon with a different proven PTC	Burden analysis provides exon-specific evidence for pathogenicity of PTC variant/s	Variable	
	PP4, BP5	Phenotype specific for disease, Variant found in case with alternative molecular basis >> Combined likelihood ratio data from calibrated analyses	Any calibrated information predictive of variant pathogenicity can be utilized	Variable	
	BP1	Missense variant in gene with primarily truncating pathogenic variants >> Missense/silent variant, with no predicted splicing, located outside a functional domain	Calibration analysis indicates that variant location outside of a known protein functional domain is a strong predictor against pathogenicity	Yes, Strong	

Figure 2: Outline of *BRCA1* and *BRCA2* VCEP specifications designated for baseline ACMG/AMP codes and criteria.

Code designations, and original criterion descriptions for codes, are derived from Richards et al 2015.⁹ For repurposed codes, the original criterion description is noted in light blue font, and a broad description is provided for the evidence type to be captured as per specifications. Evidence strength changes are recorded as follows: N/A – not applicable; No - codes used only at original specified weight; Yes - codes used with changed weight; Variable – different strength options can be applicable. Evidence strengths were informed by Bayesian modelling results.^{13; 24} Splicing-related codes were informed by parallel work.¹⁴




Figure 3: Overview of evidence supporting PM5 exon-specific weights application for premature termination codon variants in *BRCA1* (A) and *BRCA2* (B)

Exon-specific points assigned are derived from per-exon evidence, as follows: observed experimental impact on function for at least one premature termination codon (PTC) variant in an exon, to infer code PS3 for another PTC variant in the same exon (Fxn PTC, assigned 4 points); observed experimental impact on function for at least one missense substitution variant in the exon indicates no rescue of pathogenic variants due to alternative splicing, and that a PTC variant leading to nonsense mediated decay would have at minimum the same impact - used to infer code PS3_moderate for another PTC variant in the same exon (Fxn Missense, assigned 2 points); Case-control Odds Ratio (OR) ≥ 4.0 estimated for PTC variants observed in a given exon, to infer code PS4 for any PTC variant in that exon (CaCo OR ≥ 4), assigned at full strength for a statistically significant association (4 points), and at supporting strength for non-significant estimates (1 point); family history likelihood ratio (LR) estimates from heterogeneity analysis, using personal and family history profile as a predictor of pathogenicity in a clinical dataset²⁹ (Fam History LR, assigned points based on LR); standardized incidence ratio (SIR) ≥ 4.0 , for PTC variants in non-Finnish European (NFE)

probands with breast, ovarian and/or pancreatic cancer in a clinical dataset sourced from Ambry Genetics²⁹ versus the summed frequency of PTC in gnomAD NFE (Ambry SIR/OR), with $SIR \geq 4$, $P < 0.05$ was used to infer code PS4 (4 points), and $SIR \geq 4$ non-significant as PS4_supporting (1 point); identification of PTC variants in a given exon in multiple independent probands in the CIMBA (<https://cimba.ccge.medschl.cam.ac.uk/>) highly ascertained cohort of *BRCA1* and *BRCA2* pathogenic variant carriers (including patients who historically met strict clinical criteria to undergo diagnostic testing), with observation of ≥ 5 unique PTCs variant in ≥ 5 CIMBA families used to infer PP4 (CIMBA, 1 point). The per-exon evidence was summed across the different evidence types (Fxn PTC, Fxn Missense, CaCo OR ≥ 4 , Fam History LR, Ambry SIR/OR, CIMBA), to derive an exon-specific evidence strength using a points-based approach (Supporting = 1 point, Moderate = 2 points, Strong = 4 points). Based on the combined evidence, the PM5 (PTC) code can be applied as Strong evidence in favour of pathogenicity for most exons. The PM5 (PTC) code can only be applied to germline variants that meet PVS1 codes, namely nonsense and frameshift changes, including large deletions and tandem duplications. Code weight is determined by the exon in which the predicted termination codon occurs. For example, a frameshift variant in *BRCA2* exon 15 that is predicted to result in a PTC within exon 16 would use the code strength of *BRCA2* exon 16 (PM5_Strong (PTC)). Variants in the AG-GT splice site positions do not qualify for PM5 (PTC) code.




Figure 4: Overview of variant classifications assigned during pilot of VCEP specifications.

Sankey diagram shows transition in classification categories for pilot variants, from initial ClinVar classification to final classification assigned by the VCEP. The left column represents the initial ClinVar classification category/grouping of pilot variants. The central column represents classification/s by biocurators after the initial pilot phase. The right column represents the final classifications of pilot variants. Classification categories: P=Pathogenic; LP=Likely Pathogenic; VUS=Variant of uncertain significance; Conflict=conflicting; LB=Likely Benign; B=Benign. For each category/grouping, the number of variants is shown in parentheses. Final VCEP curation resulted in increased certainty in classification for all variants with initial LP/P or B/LB category, movement of three of four variants with initial VUS classification outside of this category, and resolution in classification for the nine variants with initial conflicting classification - eight reaching classification other than VUS.

References

1. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L.M., Ding, W., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266, 66-71.
2. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., and Micklem, G. (1995). Identification of the breast cancer susceptibility gene BRCA2. *Nature* 378, 789-792.
3. Spurdle, A.B., Healey, S., Devereau, A., Hogervorst, F.B., Monteiro, A.N., Nathanson, K.L., Radice, P., Stoppa-Lyonnet, D., Tavtigian, S., Wappenschmidt, B., et al. (2012). ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. *Hum Mutat* 33, 2-7.
4. Caputo, S.M., Golmard, L., Leone, M., Damiola, F., Guillaud-Bataille, M., Revillion, F., Rouleau, E., Derive, N., Buisson, A., Basset, N., et al. (2021). Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. *Am J Hum Genet* 108, 1907-1923.
5. Goldgar, D.E., Easton, D.F., Byrnes, G.B., Spurdle, A.B., Iversen, E.S., Greenblatt, M.S., and Group, I.U.G.V.W. (2008). Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. *Hum Mutat* 29, 1265-1272.
6. Goldgar, D.E., Easton, D.F., Deffenbaugh, A.M., Monteiro, A.N., Tavtigian, S.V., Couch, F.J., and Breast Cancer Information Core Steering, C. (2004). Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. *Am J Hum Genet* 75, 535-544.
7. Lindor, N.M., Guidugli, L., Wang, X., Vallee, M.P., Monteiro, A.N., Tavtigian, S., Goldgar, D.E., and Couch, F.J. (2012). A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). *Hum Mutat* 33, 8-21.
8. Thompson, D., Easton, D.F., and Goldgar, D.E. (2003). A full-likelihood method for the evaluation of causality of sequence variants from family data. *Am J Hum Genet* 73, 652-655.
9. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 17, 405-424.
10. Rehm, H.L., Berg, J.S., Brooks, L.D., Bustamante, C.D., Evans, J.P., Landrum, M.J., Ledbetter, D.H., Maglott, D.R., Martin, C.L., Nussbaum, R.L., et al. (2015). ClinGen--the Clinical Genome Resource. *N Engl J Med* 372, 2235-2242.
11. Rivera-Munoz, E.A., Milko, L.V., Harrison, S.M., Azzariti, D.R., Kurtz, C.L., Lee, K., Mester, J.L., Weaver, M.A., Currey, E., Craigen, W., et al. (2018). ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. *Hum Mutat* 39, 1614-1622.
12. Parsons, M.T., Tadini, E., Li, H., Hahnen, E., Wappenschmidt, B., Feliubadalo, L., Aalfs, C.M., Agata, S., Aittomaki, K., Alducci, E., et al. (2019). Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Hum Mutat* 40, 1557-1578.
13. Tavtigian, S.V., Greenblatt, M.S., Harrison, S.M., Nussbaum, R.L., Prabhu, S.A., Boucher, K.M., Biesecker, L.G., and ClinGen Sequence Variant Interpretation Working, G. (2018). Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. *Genet Med* 20, 1054-1060.
14. Walker, L.C., Hoya, M., Wiggins, G.A.R., Lindy, A., Vincent, L.M., Parsons, M.T., Canson, D.M., Bis-Brewer, D., Cass, A., Tchourbanov, A., et al. (2023). Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup. *Am J Hum Genet* 110, 1046-1067.
15. Pejaver, V., Byrne, A.B., Feng, B.J., Pagel, K.A., Mooney, S.D., Karchin, R., O'Donnell-Luria, A., Harrison, S.M., Tavtigian, S.V., Greenblatt, M.S., et al. (2022). Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. *Am J Hum Genet* 109, 2163-2177.
16. Cristina Fortuno, K.M., Michael Parsons, Jill S. Dolinsky, Tina Pesaran, Amal Yussuf, Jessica L. Mester, Kathleen S. Hruska, Susan Hiraki, Robert O'Connor, Raymond C. Chan, Serra Kim, Sean V. Tavtigian, David Goldgar, Paul

- A. James, Amanda B. Spurdle. Challenges and approaches to calibrating patient phenotype as evidence for cancer gene variant classification under ACMG/AMP guidelines. *Hum Mol Genet* In Press.
17. Thomassen, M., Mesman, R.L.S., Hansen, T.V.O., Menendez, M., Rossing, M., Esteban-Sanchez, A., Tudini, E., Tornngren, T., Parsons, M.T., Pedersen, I.S., et al. (2022). Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points-based ACMG/AMP approach. *Hum Mutat* 43, 1921-1944.
 18. Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A.H., Karczewski, K., Ing, A.Y., Barton, P.J.R., Funke, B., Cook, S.A., MacArthur, D., et al. (2017). Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet Med* 19, 1151-1158.
 19. Belman, S., Parsons, M.T., Spurdle, A.B., Goldgar, D.E., and Feng, B.J. (2020). Considerations in assessing germline variant pathogenicity using cosegregation analysis. *Genet Med* 22, 2052-2059.
 20. Breast Cancer Association, C., Dorling, L., Carvalho, S., Allen, J., Gonzalez-Neira, A., Luccarini, C., Wahlstrom, C., Pooley, K.A., Parsons, M.T., Fortuno, C., et al. (2021). Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *N Engl J Med* 384, 428-439.
 21. James, P.A., Fortuno, C., Li, N., Lim, B.W.X., Campbell, I.G., and Spurdle, A.B. (2022). Estimating the proportion of pathogenic variants from breast cancer case-control data: Application to calibration of ACMG/AMP variant classification criteria. *Hum Mutat* 43, 882-888.
 22. Abou Tayoun, A.N., Pesaran, T., DiStefano, M.T., Oza, A., Rehm, H.L., Biesecker, L.G., Harrison, S.M., and ClinGen Sequence Variant Interpretation Working, G. (2018). Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. *Hum Mutat* 39, 1517-1524.
 23. de la Hoya, M., Soukarieh, O., Lopez-Perolio, I., Vega, A., Walker, L.C., van Ierland, Y., Baralle, D., Santamarina, M., Lattimore, V., Wijnen, J., et al. (2016). Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. *Hum Mol Genet* 25, 2256-2268.
 24. Tavtigian, S.V., Harrison, S.M., Boucher, K.M., and Biesecker, L.G. (2020). Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. *Hum Mutat* 41, 1734-1737.
 25. Davidson, A.L., Leonard, C., Koufariotis, L.T., Parsons, M.T., Hollway, G.E., Pearson, J.V., Newell, F., Waddell, N., and Spurdle, A.B. (2021). Considerations for using population frequency data in germline variant interpretation: Cancer syndrome genes as a model. *Hum Mutat* 42, 530-536.
 26. Luo, X., Maciaszek, J.L., Thompson, B.A., Leong, H.S., Dixon, K., Sousa, S., Anderson, M., Roberts, M.E., Lee, K., Spurdle, A.B., et al. (2023). Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines. *J Med Genet* 60, 568-575.
 27. Preston, C.G., Wright, M.W., Madhavrao, R., Harrison, S.M., Goldstein, J.L., Luo, X., Wand, H., Wulf, B., Cheung, G., Mandell, M.E., et al. (2022). ClinGen Variant Curation Interface: a variant classification platform for the application of evidence criteria from ACMG/AMP guidelines. *Genome Med* 14, 6.
 28. Cline, M.S., Liao, R.G., Parsons, M.T., Paten, B., Alquaddoomi, F., Antoniou, A., Baxter, S., Brody, L., Cook-Deegan, R., Coffin, A., et al. (2018). BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genet* 14, e1007752.
 29. Li, H., LaDuca, H., Pesaran, T., Chao, E.C., Dolinsky, J.S., Parsons, M., Spurdle, A.B., Polley, E.C., Shimelis, H., Hart, S.N., et al. (2020). Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort. *Genet Med* 22, 701-708.